Skip to main content
idi
Toggle navigation
0
You have 0 notifications
Site Visitor
Site Visitor
New To Inknowvation.com?
Register now to get an access to proprietary SBIR-STTR databases!
Registration is fast and free - start your access to business-actionable information today!
Login
Site Register
SBIR-STTR Award
You are here:
Home
Search Databases
Search SBIR-STTR Awards
SBIR-STTR Award
8
CLR as a NEO Adjuvant Treatment Option for Triple Negative Breast Cancer Period of Performance
Award last edited on: 9/13/2021
Sponsored Program
SBIR
Awarding Agency
NIH : NCI
Total Award Amount
$2,292,085
Award Phase
2
Solicitation Topic Code
NCI
Principal Investigator
Benjamin Titz
Company Information
Cellectar Biosciences Inc
(
AKA
: Novelos Therapeutics Inc~Novellas)
100 Campus Drive
Madison, NJ 07932
(608) 441-8120
slichaw@novelos.com
www.cellectar.com
Location:
Multiple
Congr. District:
11
County:
Morris
Phase I
Contract Number:
----------
Start Date:
----
Completed:
----
Phase I year
2015
Phase I Amount
$292,715
Poor prognosis of triple negative breast cancer TNBC is attributable to the absence of efficacious molecularly targeted neoadjuvant therapies Micrometastases contribute to poor prognosis by increasing recurrence rate Consequently an effective treatment option that is capable of targeting and sterilizing micrometastatic disease in patients with TNBC is warranted I CLR is proposed as a neoadjuvant therapy option for TNBC patients In the first aim of this proposal I will conjugated to a tumor targeting moiety CLR Subsequently the physico chemical properties of I CLR will be characterized and the chemical reactions to maximize chemical yield and minimize the amount of chemical impurities will be optimized I CLR will be synthesized reliably with a radiochemical yield rt a radiochemical purity final product rt and chemical purity final product rt In the second aim I CLR will be characterized biologically in murine TNBC models This will include the assessment of pharmacokinetics radiation dosimetry and the investigation of normal tissue toxicities Hematological toxicity will most likely be dose limiting In the final aim efficacy studies of I CLR in an appropriate murine model of TNBC will be conducted It is hypothesize that neoadjuvant I CLR leads to reduced tumor metastasis and improved survival in clinically relevant mouse models of TNBC
Phase II
Contract Number:
----------
Start Date:
----
Completed:
----
Phase II year
2016
Phase II Amount
$1,999,370
___(NOTE: Note: no official Abstract exists of this Phase II projects. Abstract is modified by idi from relevant Phase I data. The specific Phase II work statement and objectives may differ)___ Poor prognosis of triple negative breast cancer TNBC is attributable to the absence of efficacious molecularly targeted neoadjuvant therapies Micrometastases contribute to poor prognosis by increasing recurrence rate Consequently an effective treatment option that is capable of targeting and sterilizing micrometastatic disease in patients with TNBC is warranted I CLR is proposed as a neoadjuvant therapy option for TNBC patients In the first aim of this proposal I will conjugated to a tumor targeting moiety CLR Subsequently the physico chemical properties of I CLR will be characterized and the chemical reactions to maximize chemical yield and minimize the amount of chemical impurities will be optimized I CLR will be synthesized reliably with a radiochemical yield rt a radiochemical purity final product rt and chemical purity final product rt In the second aim I CLR will be characterized biologically in murine TNBC models This will include the assessment of pharmacokinetics radiation dosimetry and the investigation of normal tissue toxicities Hematological toxicity will most likely be dose limiting In the final aim efficacy studies of I CLR in an appropriate murine model of TNBC will be conducted It is hypothesize that neoadjuvant I CLR leads to reduced tumor metastasis and improved survival in clinically relevant mouse models of TNBC
×
Login to your account
Mail sent successfully.
Enter any username and password.
Username
Password
Remember me
Login
Forgot your username?
Click here for assistance
Forgot your password?
Request new password
Don't have an account?
Sign up
Forgot username?
Mail sent successfully.
Enter username and password.
Please enter email address that is associated with your account.
Back
Submit
Still Need Help?
If you need further assistance, send us an
e-mail
and we will assist you in resetting your account.
Forgot password?
Mail sent successfully.
Enter username and password.
Please enter email address that is associated with your account.
Back
Submit
Still Need Help?
If you need further assistance, send us an
e-mail
and we will assist you in resetting your account.